JNJ·Johnson & Johnson

Johnson & Johnson is a global healthcare conglomerate operating in the pharmaceutical and medical device sectors. The company's Innovative Medicine segment focuses on prescription drugs across various therapeutic areas, while its MedTech segment offers a wide array of medical devices and technologies. This diversified business model positions JNJ as a significant player within the broader healthcare industry, leveraging its extensive R&D to deliver innovative solutions worldwide. In its most recent reported quarters, JNJ demonstrated a pattern of exceeding earnings per share estimates, with actual EPS of $2.77 in Q1 2025 and $2.77 in Q2 2025, both surpassing their respective estimates. Revenue also showed growth, with Q2 2025 revenue reaching $23.74 billion, up from $21.89 billion in Q1 2025. This performance follows a trend of positive EPS surprises in prior quarters, such as beating estimates in Q4 2024 ($2.04 actual vs. $2.01 estimate) and Q3 2025 ($2.80 actual vs. $2.76 estimate). However, the most recent Q1 2026 results showed a miss on EPS, with actual EPS of $2.70 falling short of the $2.88 estimate, alongside a revenue decline to $24.06 billion from $25.03 billion. Historically, JNJ has shown a consistent ability to grow revenue year-over-year, often accompanied by positive EPS beats, though the Q1 2026 results indicate a potential deceleration. Recent news highlights significant product advancements, including the global launch of the Shockwave C2 Aero coronary IVL catheter and positive clinical data for inflammatory bowel disease treatments and oncology candidates. These developments, coupled with strategic investments in innovation and a strong position in the growing orthopedic market, underscore JNJ's commitment to pipeline strength. Investors will be watching for continued commercial success of new product launches and the sustained performance of its pharmaceutical and MedTech segments in the face of evolving market dynamics and potential regulatory impacts.